Abstract
“What is happening with chemistry in America?” queries Matthew D. Hall, a biology group leader at the US National Center for Advancing Translational Sciences (NCATS) in a Twitter post July 8. “We’re losing postdocs to pharma after less than 1 year in our med chem labs. Is the job market that hot in chemistry?” The answer, in short, is yes. The combination of a healthy drug industry, heavy venture capital investment in start-ups, and new targets for small-molecule drugs is spurring a hiring spree, allowing some young PhD chemists, particularly in medicinal and computational chemistry, to skip the traditional years of postdoctoral training and go quickly to work in the pharmaceutical industry. The boom is great for chemists looking to start their careers, but it is raising questions about the role of the postdoc in the training of chemists today. Hall says he was prompted to start a conversation on
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
